Reversing methods of tumor multidrug resistance

Abstract

Chen Ying, Zhang Xingping. Reversing methods of tumor multidrug resistance[J]. Journal of International Oncology, 2016, 43(5): 364-367.

［1］ Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of Pgp inhibitors: skimming through several generations and scaffolds［J］. Curr Med Chem, 2012, 19(13): 1946-2025. ［2］ Vadlapatla RK, Vadlapudi AD, Pal D, et al. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes［J］. Curr Pharm Des, 2013, 19(40): 7126-7140. ［3］ Wu Q, Yang Z, Nie Y, et al. Multidrug resistance in cancer chemotherapeutics: mechanisms and Lab approaches［J］. Cancer Lett, 2014, 347(2): 159-166. DOI: 10.1016/j.canlet.2014.03.013. ［4］ Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer［J］. Biotechnol Adv, 2013, 31(8): 1397-1407. DOI: 10.1016/j.biotechadv.2013.06.004. ［5］ Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice［J］. Oncologist, 2003, 8(5): 411-424. ［6］ Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 570-594. ［7］ Tang R, Faussat AM, Perrot JY, et al. Zosuquidar restores drug sensitivity in Pglycoprotein expressing acute myeloid leukemia (AML)［J］. BMC Cancer, 2008, 8(8): 51. DOI: 10.1186/14712407851. ［8］ Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of Pglycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebocontrolled trial of the Eastern Cooperative Oncology Group 3999［J］. Blood, 2010, 116(20): 4077-4085. DOI: 10.1182/blood201004277269. ［9］ Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 609-620. ［10］袁斐, 白钢钢, 苗筠杰, 等. 中药逆转肿瘤细胞多药耐药的研究进展［J］. 中草药, 2014, 45(6): 857-863. DOI: 10.7501/j.issn.02532670.2014.06.023. ［11］ Lu WD, Qin Y, Yang C, et al. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo［J］. Clinics (Sao Paulo), 2013, 68(5): 694-701. DOI: 10.6061/clinics/2013(05)18. ［12］ Guo H, Jiang W, Liu W, et al. Extracellular domain of 41BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by antiCD3 x antiPgp bispecific diabody against human multidrugresistant leukemia［J］. Cell Immunol, 2008, 251(2): 102-108. DOI: 10.1016/j.cellimm.2008.04.006. ［13］ Grodzovski I, Lichtenstein M, Galski H, et al. IL2granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3independent apoptotic pathway［J］. Int J Cancer, 2011, 128(8): 1966-1980. DOI: 10.1002/ijc.25527. ［14］ Mizukoshi E, Nakagawa H, Kitahara M, et al. Phase Ⅰ trial of multidrug resistanceassociated protein 3derived peptide in patients with hepatocellular carcinoma［J］. Cancer Lett, 2015, 369(1): 242-249. DOI: 10.1016/ j.canlet.2015.08.020. ［15］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line［J］. DNA Cell Biol, 2011, 30(6): 413-418. DOI: 10.1089/dna.2010.1143. ［16］揭惠, 酉明巧, 刘辉, 等. 肿瘤多药耐药的发生机制及逆转策略［J］. 中华中医药学刊, 2013 (7): 1686-1690. ［17］ Binkhathlan Z, Lavasanifar A. Pglycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives［J］. Curr Cancer Drug Targets, 2013, 13(3): 326-346. ［18］ Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)［J］. FEBS Lett, 2003, 545(2/3): 144-150. ［19］ Li JM, Zhang W, Su H, et al. Reversal of multidrug resistance in MCF7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acidconjugated polyethylenimine hydroxypropylβcyclodextrin nanocarrier［J］. Int J Nanomedicine, 2015, 10: 3147-3162. DOI: 10.2147/IJN.S67146. ［20］ Tian W, Chen J, He H, et al. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications［J］. Clin Transl Oncol, 2013, 15(5): 335-342. DOI: 10.1007/s1209401209295. ［21］ Hu Y, Xu K, Yagüe E. miR218 targets survivin and regulates resistance to chemotherapeutics in breast cancer［J］. Breast Cancer Res Treat, 2015, 151(2): 269-280. DOI: 10.1007/s1054901533729. ［22］ Milane L, Ganesh S, Shah S, et al. Multimodal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology［J］. J Control Release, 2011, 155(2): 237-247. DOI: 10.1016/j.jconrel.2011.03.032. ［23］ He Q, Shi J. MSN anticancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition［J］. Adv Mater, 2014, 26(3): 391-411. DOI: 10.1002/adma.201303123. ［24］贾晋斌, 韦青燕. 阿霉素脂质体的研究进展［J］. 中国肿瘤, 2011, 20(5): 372-377. DOI: 10.1063/1.3253351. ［25］ Huang C, Li Y, Cao P, et al. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycinresistant SGC7901/ADM gastric cancer cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 488-496. DOI: 10.1007/s1159601104780. ［26］ Mao Z, Zhou J, Luan J, et al. Tamoxifen reduces Pgpmediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ERnegative human gastric cancer cells［J］. Biomedicine Pharmacother, 2014, 68(2): 179-183. DOI: 10.1016/j.biopha.2013.10.003.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Reversing methods of tumor multidrug resistance

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments